Loading company…
China-based biotech offering CDMO, CRO and analytical testing services for cell and gene therapy drugs and viral vectors.
Ubrigene provides CRO and CDMO services for innovative cell and gene therapy drugs, including clinical-grade viral vectors, and offers analytical testing alongside therapeutic drugs. Products include DNA, RNA, virus, kits and proteins. Established in 2015, the company has GMP production bases in Maryland, Suzhou, Jinan, Guangzhou and Beijing, and in December 2024 raised approximately CNY 200 million in pre-Series D funding. It is at the Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in